Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Radionuclide Therapy (RNT) with Lu-DOTATATE targeting somatostatin receptors (SSTRs) in neuroendocrine tumours (NET) has been successfully used in routine clinical practice, mainly leading to stable disease. Radiobiology holds promise for RNT improvement but is often extrapolated from external beam radiation therapy (EBRT) studies despite differences in these two radiation-based treatment modalities. In a panel of six human cancer cell lines expressing SSTRs, common radiobiological endpoints (i.e., cell survival, cell cycle, cell death, oxidative stress and DNA damage) were evaluated over time in Lu-DOTATATE- and EBRT-treated cells, as well as the radiosensitizing potential of poly (ADP-ribose) polymerase inhibition (PARPi). Our study showed that common radiobiological mechanisms were induced by both Lu-DOTATATE and EBRT, but to a different extent and/or with variable kinetics, including in the DNA damage response. A higher radiosensitizing potential of PARPi was observed for EBRT compared to Lu-DOTATATE. Our data reinforce the need for dedicated RNT radiobiology studies, in order to derive its maximum therapeutic benefit.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9604190PMC
http://dx.doi.org/10.3390/ijms232012369DOI Listing

Publication Analysis

Top Keywords

radiobiological mechanisms
8
mechanisms induced
8
induced lu-dotatate
8
external beam
8
beam radiation
8
radiation therapy
8
common radiobiological
8
dna damage
8
radiosensitizing potential
8
understanding radiobiological
4

Similar Publications

The Power of Precision: Unravelling the Radiobiology of Targeted Radionuclide Therapy.

Clin Oncol (R Coll Radiol)

August 2025

School of Biomedical Engineering and Imaging Sciences, King's College London, London, United Kingdom. Electronic address:

Targeted radionuclide therapy (TRT) involves systemic administration of a radionuclide attached to a cancer-targeting moiety. It has been proven to be a promising approach for primary cancer and metastasis treatment with minimal damage to surrounding tissues. TRT integrates the precision of molecular targeting with the therapeutic efficacy of radiation.

View Article and Find Full Text PDF

Does ionising radiation increase the risk of cancer even at low doses? If so, what is the magnitude of risk at these low doses? This knowledge is a central component of radiation protection. In general, radiation protection relies on the linear no-threshold (LNT) model, which is based on scientific findings. According to the LNT model, the radiation-related risk of cancer decreases proportionally with radiation dose and this applies even down to very low radiation doses.

View Article and Find Full Text PDF

Short and long-term effects on the thyroid proteome after 131I exposure.

Radiat Prot Dosimetry

August 2025

Department of Medical Radiation Sciences, Institute of Clinical Sciences, Sahlgrenska Academy, University of Gothenburg, Sahlgrenska University Hospital, SE 413 45 Gothenburg, Sweden.

131I is recognised, both for its significance in nuclear medicine, and for its association with a rise in paediatric but not adult thyroid cancer cases following the Chornobyl accident. However, the detailed radiobiological mechanisms underlying 131I effects on the thyroid remain unknown to date. In the present study, 1 kBq or 100 kBq 131I was administered to mice that were euthanised after 48 h, 3 weeks or 6 months.

View Article and Find Full Text PDF

Evaluation of a Rhenium(I) Complex and Its Pyridostatin-Containing Chelator as Radiosensitizers for Chemoradiotherapy.

Molecules

August 2025

Centro de Ciências e Tecnologias Nucleares, Instituto Superior Técnico, Universidade de Lisboa, Campus Tecnológico e Nuclear, Estrada Nacional 10, Km 139.7, 2695-066 Bobadela LRS, Portugal.

The use of radiosensitizers is a beneficial approach in cancer radiotherapy treatment. However, the enhancement of radiation effects on cancer cells by radiosensitizers involves several different mechanisms, reflecting the chemical nature of the radiosensitizer. G-quadruplex (G4) DNA ligands have emerged in recent years as a potential new class of radiosensitizers binding to specific DNA sequences.

View Article and Find Full Text PDF

Stereotactic body radiotherapy (SBRT) delivers ablative radiation doses with sub-millimeter precision. Radiogenomic studies, meanwhile, provide insights into how tumor-intrinsic genetic factors influence responses to such high-dose treatments. This review explores the radiobiological mechanisms underpinning SBRT efficacy, emphasizing the roles of DNA damage response (DDR) pathways, tumor suppressor gene alterations, and inflammatory signaling in shaping tumor radiosensitivity or resistance.

View Article and Find Full Text PDF